OBJECTIVE: A cross-sectional study of mixed connective tissue disease (MCTD) was performed to determine if there were identifiable differences in the clinical expression of MCTD associated with race or ethnicity. METHODS: Miami, Florida, and Midwestern US (Missouri) Caucasian MCTD cohorts were studied. Clinical and laboratory features of the 2 MCTD cohorts were compared. A concurrently collected cohort of Sm-positive patients with systemic lupus erythematosus (SLE) was studied as a control. Disease activity and severity and functional status were measured. CD4+CD25(high)-expressing T-regulatory cells were enumerated and serum soluble L selectin was measured as biomarkers of disease activity. RESULTS: The Miami and Missouri Caucasian MCTD groups, while differing from the SLE group, were largely similar; however, gastroesophageal reflux, sclerodactyly, and malar rash were significantly more frequent in the Missouri MCTD group and alopecia was more frequent in the Miami MCTD group. Significant clinical and laboratory differences were found between the Miami MCTD and Miami SLE groups despite similar disease duration, activity, severity and functional status. Raynaud's phenomenon (RP), hand swelling, synovitis, myositis, and sclerodactyly were all significantly more common in RNP-positive MCTD versus Sm-positive SLE subjects. CONCLUSION Ethnic differences were observed in the frequency of end-organ involvement in the Miami MCTD versus the Missouri Caucasian MCTD groups. Clinical and laboratory features of all MCTD groups were clearly different from the SLE group, despite similar disease activity, disease severity, and functional status. Disease activity measures appeared to behave similarly as valid measures of disease activity in SLE and MCTD.
OBJECTIVE: A cross-sectional study of mixed connective tissue disease (MCTD) was performed to determine if there were identifiable differences in the clinical expression of MCTD associated with race or ethnicity. METHODS: Miami, Florida, and Midwestern US (Missouri) Caucasian MCTD cohorts were studied. Clinical and laboratory features of the 2 MCTD cohorts were compared. A concurrently collected cohort of Sm-positive patients with systemic lupus erythematosus (SLE) was studied as a control. Disease activity and severity and functional status were measured. CD4+CD25(high)-expressing T-regulatory cells were enumerated and serum soluble L selectin was measured as biomarkers of disease activity. RESULTS: The Miami and Missouri Caucasian MCTD groups, while differing from the SLE group, were largely similar; however, gastroesophageal reflux, sclerodactyly, and malar rash were significantly more frequent in the Missouri MCTD group and alopecia was more frequent in the Miami MCTD group. Significant clinical and laboratory differences were found between the Miami MCTD and Miami SLE groups despite similar disease duration, activity, severity and functional status. Raynaud's phenomenon (RP), hand swelling, synovitis, myositis, and sclerodactyly were all significantly more common in RNP-positive MCTD versus Sm-positive SLE subjects. CONCLUSION Ethnic differences were observed in the frequency of end-organ involvement in the Miami MCTD versus the Missouri Caucasian MCTD groups. Clinical and laboratory features of all MCTD groups were clearly different from the SLE group, despite similar disease activity, disease severity, and functional status. Disease activity measures appeared to behave similarly as valid measures of disease activity in SLE and MCTD.
Authors: M G Danieli; P Fraticelli; F Franceschini; R Cattaneo; A Farsi; A Passaleva; M Pietrogrande; F Invernizzi; M Vanoli; R Scorza; M G Sabbadini; R Gerli; A Corvetta; G Farina; F Salsano; R Priori; G Valesini; G Danieli Journal: Clin Exp Rheumatol Date: 1999 Sep-Oct Impact factor: 4.473
Authors: E Bodolay; Z Csiki; Z Szekanecz; T Ben; E Kiss; M Zeher; G Szücs; K Dankó; G Szegedi Journal: Clin Exp Rheumatol Date: 2003 May-Jun Impact factor: 4.473
Authors: A J Swaak; H G van den Brink; R J Smeenk; K Manger; J R Kalden; S Tosi; A Marchesoni; Z Domljan; B Rozman; D Logar; G Pokorny; L Kovacs; A Kovacs; P G Vlachoyiannopoulos; H M Moutsopoulos; H Chwalinska-Sadowska; B Dratwianka; E Kiss; N Cikes; A Branimir; M Schneider; R Fischer; S Bombardieri; M Mosca; J S Smolen Journal: Rheumatology (Oxford) Date: 1999-10 Impact factor: 7.580
Authors: J Font; P Pizcueta; M Ramos-Casals; R Cervera; M García-Carrasco; M Navarro; M Ingelmo; P Engel Journal: Clin Exp Immunol Date: 2000-01 Impact factor: 4.330
Authors: J A Somarelli; A Mesa; R Rodriguez; R Avellan; L Martinez; Y J Zang; E L Greidinger; R J Herrera Journal: Lupus Date: 2011-03 Impact factor: 2.911
Authors: M F Carpintero; L Martinez; I Fernandez; A C Garza Romero; C Mejia; Y J Zang; R W Hoffman; E L Greidinger Journal: Lupus Date: 2015-03-02 Impact factor: 2.911
Authors: D P Ascherman; Y Zang; I Fernandez; E S Clark; W N Khan; L Martinez; E L Greidinger Journal: Arthritis Rheumatol Date: 2018-07-25 Impact factor: 10.995